Jun Sato

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh et al. · The Lancet Oncology · 2020 · 203 citations

Oncology, Metastatic Thymic Carcinoma, Metronomic Therapy +5

Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model

Takukyu Sha, Mie Sunamoto, Tomoyuki Kitazaki et al. · European Journal of Pharmacology · 2007 · 175 citations

Inflammation, Toll-like Receptors, Cytokine +11

Activation of Intestinal Mucosal Immunity in Tumor‐bearing Mice by Lactoferrin

Wenping Wang, Masaaki Iigo, Jun Sato et al. · Japanese Journal of Cancer Research · 2000 · 137 citations · Full text

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Ken Masuda, Hidehito Horinouchi, Midori Tanaka et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 91 citations · Full text

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori et al. · Clinical Cancer Research · 2021 · 90 citations · Full text